WOBURN, MASSACHUSETTS, April 2, 2012 — BioProcess Technology Consultants (BPTC), a leading global biopharmaceutical Chemistry, Manufacturing, and Controls (CMC) consulting company, has promoted Dawn Ecker and Rick Stock to the position of Consultant.
Rick Stock, Ph.D., an Associate Consultant with BPTC since 2005, has helped establish BPTC’s process economic modeling capabilities providing clients with key decision making tools to evaluate development and manufacturing programs, estimate costs, and assess process feasibility. His models also help clients determine how new technologies or process changes can impact manufacturing costs and facility utilization. Previously with BioPharm Services, Inc., Dr. Stock designed sophisticated models of biomanufacturing processes for such clients as Amgen, Centocor, and Millennium. Prior to joining BioPharm Services, he was Assistant Director of a pilot manufacturing facility at Worcester Polytechnic Institute (WPI). He also founded Natural Biopolymers, LLC, a company which developed a process for producing a novel pharmaceutical-grade biopolymer. He holds a Ph.D. in Biochemical Engineering from WPI.
Since joining BPTC in 2007 as Associate Consultant, Dawn M. Ecker, M.S., has been responsible for building and maintaining BPTC’s proprietary Biomanufacturing Supply and Pipeline Product Databases. BPTC’s databases are frequently used to help clients identify manufacturing capacity, develop manufacturing strategies, and assess the market potential for innovative products and services. Ms. Ecker is also a principal author of the company’s recently published report, The State of Mammalian Cell Culture Biomanufacturing. She was formerly a Research Fellow at the University of Massachusetts, Amherst, where she managed the Core Sequencing Facility. She previously worked for BioPharm Services, Capsule Technologies, and Phytera. She holds a B.S. in Microbiology/Biotechnology from Quinnipiac University and a M.S. in Biology from WPI.
“Rick has developed valuable process economic models for estimating manufacturing costs and helping clients with manufacturing strategy decisions. These models also help clients determine the viability of innovative process technologies,” said Thomas C. Ransohoff, Vice President of BPTC. “Dawn has helped develop BPTC’s proprietary databases into a robust knowledgebase that serves as the foundation for our well-received reports and presentations as well as for critical client analyses. We are proud of the accomplishments and contributions Rick and Dawn have made to the growth of BPTC, and we look forward to their continued in-depth analysis and practical guidance for BPTC’s clients.”
About BioProcess Technology Consultants
Founded in 1994, BPTC is the recognized worldwide leader in biologics CMC consulting, providing a full range of technical, regulatory, and strategic assistance to biopharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The company works with clients to find solutions to the challenges of producing biopharmaceutical supply from clone to commercial®. BPTC helps clients develop manufacturing processes and strategies and assists in establishing product discovery and process development programs that enhance the overall value of client companies. BPTC also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more information about BPTC, visit <> and follow the Company on Twitter at bptcGlobal or LinkedIn at <>.